2. Signaling Pathways
  3. GPCR/G Protein
  4. GCGR
  5. GCGR Agonist

GCGR Agonist

GCGR Agonists (55):

Cat. No. Product Name Effect Purity
  • HY-13443
    Exendin-4
    		Agonist 99.98%
    Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
  • HY-P0014
    Liraglutide
    		Agonist 99.68%
    Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
  • HY-114118
    Semaglutide
    		Agonist 99.84%
    Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.
  • HY-P1731B
    Tirzepatide hydrochloride
    		Agonist 99.82%
    Tirzepatide hydrochloride (LY3298176 hydrochloride) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes.
  • HY-121835
    GLP-1R agonist 2
    		Agonist
    GLP-1R agonist 2 (compound 2) is a potent GLP-1R agonist. GLP-1R agonist 2 has the potential for the research of metabolic diseases like Type2 Diabetes and Obesity.
  • HY-P2221B
    Glepaglutide acetate
    		Agonist 98.06%
    Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease.
  • HY-112185
    Orforglipron
    		Agonist 98.31%
    Orforglipron (LY3502970) (GLP-1 receptor agonist 1) is a GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67.
  • HY-114118A
    Semaglutide TFA
    		Agonist 99.90%
    Semaglutide TFA, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.
  • HY-103546
    BETP
    		Agonist 99.28%
    BETP is an agonist of glucagon-like peptide-1 (GLP-1) receptor, with EC50s of 0.66 and 0.755 μM for human and rat GLP-1 receptor, respectively.
  • HY-P2625
    GLP-2(3-33)
    		Agonist 99.32%
    GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC50=5.8 nM).
  • HY-P1024
    GLP-2(1-33)(human)
    		Agonist 99.18%
    GLP-2(1-33) (human) is an enteroendocrine hormone which can bind to the GLP-2 receptor and stimulate the growth of intestinal epithelium.
  • HY-13443A
    Exendin-4 acetate
    		Agonist 99.44%
    Exendin-4 acetate (Exenatide acetate), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
  • HY-P1144
    Oxyntomodulin
    		Agonist 98.00%
    Oxyntomodulin, a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist.
  • HY-P2231A
    Cotadutide acetate
    		Agonist 98.01%
    Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D).
  • HY-P0119A
    Lixisenatide acetate
    		Agonist 98.53%
    Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).
  • HY-112679
    GLP-1 receptor agonist 2
    		Agonist 98.70%
    GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.
  • HY-N0630
    Shanzhiside methyl ester
    		Agonist 98.57%
    Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance.
  • HY-P0165
    Taspoglutide
    		Agonist 98.21%
    Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM.
  • HY-P0119
    Lixisenatide
    		Agonist
    Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).
  • HY-P1731
    Tirzepatide
    		Agonist
    Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes.